Do you see a role for ultra-low-dose immunotherapy in your patients with relapsed or refractory solid tumors, and if so, in which clinical scenarios?

To date, there is not enough definitive data to support the use of low-dose immunotherapy. Moreover, ultra-low-dose nivolumab (20 mg Q2W or Q3W) has phase III evidence demonstrating an OS advantage over salvage chemotherapy in pretreated solid tumors, with a favorable toxicity and QoL profile. Its s...